Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TY LC
Sell Sell Sell!
GoupGoupGoup is Tony? Are you still in this dog with fleas?
Jim The Nut Cramer...On INO: Amid the FDA halting the company's COVID-19 vaccine trial, Cramer says "there are better fish to fry" in this industry and would get out of that company.
What a putz. It was not halted. It was paused for the device not the medicine. If he says sell that means BUY!!!
T2 Biosystems (TTOO)
Moving on to another player in the diagnostic space, T2 Biosystems manufactures molecular diagnostic instruments and test panels. While the company has struggled in the past, Leerink argues that its $1.33 share price presents an opportunity to get in on this turnaround story.
Firm analyst Puneet Souda, who also covers HTGM, points out that part of the excitement surrounding this name is related to its COVID-19 testing solution (sepsis rule-out test). During its Q2 2020 earnings call, TTOO stated that there has been serious demand for the test, with it specifically seeing increased use from hospitalized patients who have a greater risk of developing secondary co-infections such as sepsis.
It should be noted that TTOO has partnered with Hackensack Meridian Health to develop and validate the COVID-19 assay on the T2Dx platform. The system can provide results in less than two hours, with clinical data demonstrating a sensitivity of 95% and specificity of 100%. As for the daily throughput, it lands at 60-80 tests. With all of the necessary filings submitted to the FDA for Emergency Use Authorization (EUA) approval, TTOO has started selling the test to clinical labs.
Expounding on this, Souda commented, “Management expects all 60 placements in the 2020 financial guidance to be entirely driven by COVID demand and has solid visibility into 2H – impressive in our view given the lack of instrument adoption in 1H20. TTOO hopes to leverage current COVID-19 demand to increase T2Dx install base and expand sepsis-related revenue over time – as the pandemic inevitably subsides.”
Given that the COVID test is expected to provide a significant near-term revenue boost, management reinstated its FY20 revenue guidance of $18-$20 million, which is above the consensus estimate.
If that wasn’t enough, Souda calls the efforts of newly appointed CEO John Sperzel encouraging, who is working to execute on his top priorities. These include accelerating sales growth through a focus on utilization, reducing TTOO's cost structure and advancing the product pipeline.
Specifically looking at utilization, in Q2, TTOO’s U.S. annuity per system increased 51% quarter-over-quarter, from $50,000 per system to over $75,000 per system, due to rising demand for its FDA-approved fungal candida test. This doesn’t factor in any benefit from the COVID tests.
On top of this, TTOO strengthened its balance sheet, with its pro-forma cash position now coming in at $69 million. As its pipeline also includes a Lyme disease test, a testing instrument and several other test panels, Souda likes what he’s seeing.
To this end, Souda sides with the bulls. Along with an Outperform (i.e. Buy) rating, he keeps a $3 price target on the stock. This target puts the upside potential at 123%.
Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been published in the last three months. Therefore, the message is clear: TTOO is a Strong Buy. With a $3.25 average price target, shares could soar 152% in the next year.
These 3 Penny Stocks Could Rack up Triple-Digit Gains, Says Leerink
T2 Biosystems (TTOO)
Moving on to another player in the diagnostic space, T2 Biosystems manufactures molecular diagnostic instruments and test panels. While the company has struggled in the past, Leerink argues that its $1.33 share price presents an opportunity to get in on this turnaround story.
Firm analyst Puneet Souda, who also covers HTGM, points out that part of the excitement surrounding this name is related to its COVID-19 testing solution (sepsis rule-out test). During its Q2 2020 earnings call, TTOO stated that there has been serious demand for the test, with it specifically seeing increased use from hospitalized patients who have a greater risk of developing secondary co-infections such as sepsis.
It should be noted that TTOO has partnered with Hackensack Meridian Health to develop and validate the COVID-19 assay on the T2Dx platform. The system can provide results in less than two hours, with clinical data demonstrating a sensitivity of 95% and specificity of 100%. As for the daily throughput, it lands at 60-80 tests. With all of the necessary filings submitted to the FDA for Emergency Use Authorization (EUA) approval, TTOO has started selling the test to clinical labs.
Expounding on this, Souda commented, “Management expects all 60 placements in the 2020 financial guidance to be entirely driven by COVID demand and has solid visibility into 2H – impressive in our view given the lack of instrument adoption in 1H20. TTOO hopes to leverage current COVID-19 demand to increase T2Dx install base and expand sepsis-related revenue over time – as the pandemic inevitably subsides.”
Given that the COVID test is expected to provide a significant near-term revenue boost, management reinstated its FY20 revenue guidance of $18-$20 million, which is above the consensus estimate.
If that wasn’t enough, Souda calls the efforts of newly appointed CEO John Sperzel encouraging, who is working to execute on his top priorities. These include accelerating sales growth through a focus on utilization, reducing TTOO's cost structure and advancing the product pipeline.
Specifically looking at utilization, in Q2, TTOO’s U.S. annuity per system increased 51% quarter-over-quarter, from $50,000 per system to over $75,000 per system, due to rising demand for its FDA-approved fungal candida test. This doesn’t factor in any benefit from the COVID tests.
On top of this, TTOO strengthened its balance sheet, with its pro-forma cash position now coming in at $69 million. As its pipeline also includes a Lyme disease test, a testing instrument and several other test panels, Souda likes what he’s seeing.
To this end, Souda sides with the bulls. Along with an Outperform (i.e. Buy) rating, he keeps a $3 price target on the stock. This target puts the upside potential at 123%.
Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been published in the last three months. Therefore, the message is clear: TTOO is a Strong Buy. With a $3.25 average price target, shares could soar 152% in the next year.
Smart Boiler, smart
Spec plays TTOO $1.95 and SNRE $12
Last time..LOAD INO
Where do you find this crap? Ignore and wait to see what Tony says on the 4th.
INO is about to run!
Bob had his chance in 2014. He blew it
Bob had his chance in 2014. He blew it
Is Brian still screwing everyone? Man, I thought he converted to the other side?
Load zone on INO, TTOO and SRNE!
Time to Load up on INO, TTOO and SRNE
Time to Load up on INO, TTOO and SRNE
NY Times article on INO
https://www.nytimes.com/2020/06/13/science/vaccine-coronavirus-inovio.html
INO on alert. Big move coming over the next week
INO on alert...Big move coming
INO about to blast off
If Bobby is involved I highly doubt it
Same to MOMO. Is COHO a back the truck up and load?
Watching MCOA, COHO, CWNR (Shell sale)
Watching this puppy for nice push MOMO
Is Bob selling the shell?
Hearing a big run is coming
Time to slap this puppy one more time!
Even if the Fed cuts rates to zero, market bear David Rosenberg predicts a recession is less than 12 months away
Market is underestimating the odds of more interest rate cuts: David Rosenberg
Despite the Federal Reserve’s latest efforts to boost the economy, long-time market bear David Rosenberg warns a recession is coming.
The Gluskin Sheff chief economist and strategist predicts economic growth in the U.S. will turn negative sooner than most investors anticipate — setting the stage for a painful market pullback.
“There’s a recession coming in the next 12 months,” he said last Thursday on CNBC’s “Futures Now.
The Fed lowered its benchmark interest rate last Wednesday by a quarter point. Fed Chairman Jerome Powell signaled rates would only be cut again if there’s new evidence the economy is softening. However, Powell said he didn’t expect that to happen.
“The only reason that he said that he’s optimistic on the outlook is because of exactly what the Fed is doing which is breathing stimulus back into the economy,” said Rosenberg, who came into 2019 with a recession warning and has been known as a perma-bear on Wall Street for decades.
Yet, U.S. growth hasn’t gone negative this year. Plus, the S&P 500 and Dow are up more than 19% and 15%, respectively.
But according to Rosenberg, it’s just a matter of time until economic data sours and Powell is forced to resume easing in the coming months.
“I think that they’ll go in October and December and through 2020,” he added.
Whether the Fed cuts all the way to zero or not, Rosenberg speculates the outcome will be the same: Recession.
“The economy is already slowing down,” Rosenberg said. “Earnings are actually contracting.”
I wonder if Michael Sheppard is still alive? Another dormant shell.
Not sure if Bob is involved in bringing anything to this shell. Not many shares available.
How many shares outstanding?
Regional bank mergers coming imo. The first was today.
Short the market. Big drop coming
Are you still wasting you hard earned money on Brian Sorrentino?
What's hot Boiler?
Group, you have my vote. This guy could talk a starving pitbull of a meat truck.
Slapfest? He was lucky that was it was imo. The guy can’t stop lying. He has has daily conversations with himself in mirror asking what should I lie about today?
The guy running this is a moron. No clue what he is doing.
GE Looks good here